This research service focuses on the 4 broad segments of the regenerative medicine market, namely cell therapy, gene therapy, tissue engineering, and small molecules and biologics. A detailed overview of the cell therapy segment, including the major commercialised products and products in development, has been provided. Additionally, key clinical milestones, timelines of key clinical events, key companies to watch, and a strategic partnership assessment in the global regenerative market have been included. An overview of the other segments—gene therapy, tissue engineering, and small molecules and biologics—has also been provided.
Regenerative medicine aims to augment, repair, replace, or regenerate tissue and organs damaged by disease, injury, or the natural aging process.
While a vast majority of currently available treatments for chronic and fatal diseases are palliative or delay disease progression, regenerative medicine is uniquely capable of altering the underlying disease mechanism.
The regenerative medicine market can primarily be segmented into major classes based on different therapeutic approaches/technologies including: Cell therapy (CT); gene therapy (GT); tissue engineering (TE), including synthetic materials, biomaterials, and scaffolds; and small molecules and biologics.
Although regenerative medicine is in a relatively early stage of development, a significant number of products, particularly cell therapy (CT)-based products and tissue engineered (TE) products, are already commercially available on the market.
According to the Alliance for Regenerative Medicine (ARM), in 2012 nearly stem-cell transplants were performed worldwide and over patients were treated with cell therapy products, generating revenue of over $million.
2012 witnessed the approval of the highest number () of cell-therapy products by regulatory agencies globally, while 5 such approvals were granted between 2009 and 2011, and none from 2002 to 2008.
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Global Site License Fulfilled By Publisher